Skip to main content

DREF #Operation: #Ethiopia #Marburg #Outbreak 2025 (MDRET039) (IFRC, Dec. 1 '25)

 


Description of the Event

Date when the trigger was met12-11-2025

What happened, where and when?

-- On 14 November 2025, the Federal Ministry of Health (FMOH), in collaboration with the Ethiopian Public Health Institute (EPHI), issued a press release declaring an outbreak of Marburg virus disease in the South Region of Ethiopia

-- As of 26 November 2025, 78 laboratory tests have been conducted, of which twelve confirmed cases, including seven confirmed deaths, have been reported, three cases remain probable

-- Of the twelve confirmed cases, five are currently alive, three on treatment, and two discharged

-- More than 300 contacts have been identified and are under active follow-up. 

-- Given the high fatality potential and rapid transmissibility of Marburg, (MVD) an immediate and coordinated public health response is essential. 

- Early detection, isolation, contact tracing, and community sensitization are critical to prevent further spread by strengthening infection prevention and control (IPC) in health facilities, ensuring the safety of health workers, mobilizing rapid response teams (RRTs), and effective risk communication are key priorities at this stage.

-- An urgent response is warranted due to the potential for rapid local and cross-regional transmission, and significant public health threat associated with hemorrhagic fevers. 

-- Delayed intervention could result in high morbidity and mortality, community panic and overburdening of the health system. 

-- Immediate action will help contain the outbreak source, interrupt transmission chains, and protect both the affected population and health workers while laboratory confirmation and epidemiological investigations continue.

Source: 


Link: https://reliefweb.int/report/ethiopia/dref-operation-ethiopia-marburg-outbreak-2025-mdret039

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...